Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02785172 | Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis | PHASE2 | COMPLETED | 154 | — | — | Apr 1, 2016 | Jan 1, 2017 | Aug 20, 2020 | 14 | United States |
Treatment success defined as at least a 2-grade improvement from Baseline in the Investigator's Global Assessment (IGA) score and an IGA score equating to "clear" or "almost clear". The IGA score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe).
| Arm | Type | Description |
|---|---|---|
| IDP-118 Lotion | EXPERIMENTAL | Lotion |
| Ultravate Cream | ACTIVE_COMPARATOR | Cream |
| IDP-118 Vehicle Lotion | ACTIVE_COMPARATOR | Lotion |
| IDP-118 Vehicle Cream | ACTIVE_COMPARATOR | Cream |
| Name | Type | Description |
|---|---|---|
| IDP-118 Vehicle Lotion | DRUG | Vehicle |
| IDP-118 Vehicle Cream | DRUG | Vehicle |
| IDP-118 Lotion | DRUG | Lotion |
| Ultravate Cream | DRUG | Cream |
Key Inclusion Criteria: * Male or female, of any race, at least 18 years of age (inclusive). * Freely provides both verbal and written informed consent. * Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA (Body Surface Area) of at least 3%, but no more than 12%. Th...